Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 1999

View Archived Issues

Theratechnologies and Atrix sign bone research collaboration

Licensing opportunity from NIH: antisense oligonucleotides for treating Crohn's disease

AS-924, a newly synthesized bifunctional ceftizoxime prodrug, shows good oral absorption

Lexicon Genetics grants sublicense to Avatar BioSci for use of gene-trapping technology

Axcan completes acquisition of 50% of Bonne Sante and Czet Pharma

Preliminary results of two Remune studies published in the Journal of Infectious Diseases

RPR reports new naphthyl-piperazinone antitumor agents

New NOS inhibitors in the pipeline at Schering AG

Topoisomerase poisons emerge from research at U.S. university

MCP-1/RANTES inhibitors in early development at AstraZeneca

Full agenda for next week's Oncologic Drugs Advisory Committee meeting

Relenza launched in U.K. in time for this year's flu season

Another market introduction for Merck's short-acting antiplatelet agent Aggrastat

Roberts to market Fareston in the U.S.

NexMed reports progress with topical treatments for sexual dysfunction

Atairgin and Washington State University to develop new therapeutic applications

Israeli group designs new family of nonpeptide, nonsulfhydryl Ras farnesylation inhibitors

Novartis initiates clinical trials using Emisphere's oral drug delivery technology

Two small-molecule anti-HIV compounds targeting gp41 identified at New York Blood Center

FDA approves new indications for Zerit and Videx

Rofecoxib, a new COX-2 inhibitor, effective against fever in monkeys and humans

Cellegy testosterone gel completes phase II trial

CAT and AstraZeneca form antibody research collaboration

InSite Vision receives milestone payment for ISV-205 development

Pyridorin enters clinical trials for treatment of diabetic kidney disease

BTS-79018 selected for clinical development as atypical antipsychotic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...